Gilead in $21 bn deal for Immunomedics

US pharmaceutical giant Gilead Sciences confirmed Sunday that it is buying American biotech firm Immunomedics, which makes a breast cancer drug, for $21 billion.


Dismantling structural racism in nursing

Confronting the uncomfortable reality of systemic racism—the system that creates and maintains racial inequality in every facet of life for people of color—is having a national heyday. But calling out this injustice and ...

page 1 from 782